FOLH1 and neoplasm: To date, several disease-related or patient-specific factors that could affect treatment response have been considered such as ECOG score, laboratory results, PSMA heterogenicity, [18F]FDG uptake, tumor localization (bone/lymph node/visceral), high versus low volume disease, and DNA-damage repair mutations [6, 8, 10, 13–20].